[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-neuropathic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-neuropathic-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,93,128,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100580237","evaluating-laser-photobiomodulation-for-the-treatment-of-neuropathic-pain-in-chemotherapy-induced-peripheral-neuropathy-in-cancer-patients-100580237",false,"NCT06834685","Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients","Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy: a Randomized, Non-comparative, Placebo-controlled, Single-blinded, Phase II Clinical Trial in Cancer Patients","NEUROdoux","Inclusion Criteria:\n\n* Male or female aged 18 years minimum;\n* Patient treated at the Montpellier Cancer Institute for a cancer (whatever the location) requiring a chemotherapy;\n* Patient with significant NP defined as a score of 4 at the clinician-rated DN4 ;\n* Patient with a NP for at least 3 months after the end of an adjuvant or neo-adjuvant chemotherapy;\n* Women of childbearing potential must have a pregnancy urinary test within a maximum of 7 days before starting the study treatment. A negative result must be documented before study treatment is started. Women without reproductive potential are postmenopausal women or women who have undergone permanent sterilisation (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy);\n* Effective contraception for women of childbearing age\n* Patient having signed informed consent prior to any study procedure;\n* Patient affiliated to a French social protection system;\n* Patient sufficiently fluent in French to complete questionnaires, as the investigator clinical discretion.\n\nExclusion Criteria:\n\n* Patient unable to come twice a week to the Montpellier Cancer Institute;\n* Patient unable to sit for a 30-minutes period;\n* Patient with an open wound or ulcer on the treatment area;\n* Patient whose diagnosis of peripheral neuropathy is due to another cause (n.b., diabetes without neuropathy will not be a specific exclusion);\n* Patient with uncontrolled psychiatric illness or neurocognitive impairment that may interfere with assessments, as the investigator clinical discretion;\n* Patient whose estimated life expectancy is less than 3 months, as estimated by a clinical investigator;\n* Patient using another concurrent non-pharmacological intervention or complementary therapy for neuropathy during the study;\n* Patient who has been treated with CAPSAISINE during the previous 3 months;\n* Patient with pacemaker;\n* Epileptic patient;\n* Patient with photosensitive medications, or any medical condition causing sensitivity to light (n.b., Lupus);\n* Pregnant and\u002For breastfeeding woman;\n* Patient with primary tumor and\u002For metastases in areas to be treated by BPM (i.e., hands and\u002For feet);\n* Patient with pre-existing eye disease (such as maculopathy, glaucoma, cataract and retinal lesions), or a history of family eye diseases;\n* Patient who has been already been treated with photobiomodulation on the area of interest.\n* Participation in another concomitant clinical study with neuropathic pain or chemo-induced peripheral neuropathy as the primary endpoint.\n* Presence of a tattoo on the area to be treated.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","Chemotherapy-induced peripheral neuropathy (CIPN) (including taxanes, platinum, al pervenche from Madagascar alkaloids...), is a frequent secondary effect of treatments: 68% at 1-month post-chemotherapy, 60% at 3 months and 30% after 6 months. Symptoms associated with CIPN are usually symmetric and bilateral (typical distribution in \"gloves and socks\") inducing sensory alterations, paresthesias, dysesthesias, numbness and pain. Neuropathic Pain (NP) is an important characteristic of CIPN, affects 25-80% of patients with CIPN, and reduces quality of life (e.g., concomitant psychological distress, risks of falls, risks of neurocognitive impairments, and sleep disorders).\n\nIn severe cases, it is even necessary to delay and\u002For reduce the dose of chemotherapy. The benefit of drug interventions on NP remains limited. To date, there are no proven preventive strategies and few evidence-based treatment options for CIPN. Also, the use of complementary or non-pharmacological interventions are common, including photobiomodulation (PBM).\n\nPBM is the therapeutic use of non-ionizing laser light for its anti-inflammatory and regenerative effects. Its use is currently recommended only for the prevention of oral mucositis related to cancer treatments. Recent preliminary clinical evidence suggests that PBM may be beneficial to established CIPN, with safety and improvement beyond the intervention. However, to date, clinical trials are rare, have methodological weaknesses, and\u002For focus on global CIPN. The overall objectives of the study are therefore to assess the effectiveness, feasibility and safety of the PBM for treating NP in the CIPN.",[27,28],"Cancer Survivors","Peripheral Neuropathic Pain","RECRUITING","2026-06-02",{"date":32,"type":33},"2026-06-04","ACTUAL",{"date":35,"type":33},"2025-10-07",{"date":37,"type":21},"2028-12",{"name":39,"class":40},"Institut du Cancer de Montpellier - Val d'Aurelle","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":5},"100466289","phase-2-proof-of-concept-trial-of-cannabis-derivatives-in-neuropathic-pain-100466289","NCT05351801","Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain","CAN","Inclusion Criteria:\n\n* Able to provide written consent\n* Veterans 21 years and older at the date of screening\n* Meet diagnostic criteria for neuropathic pain as defined by the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG)\n* Meet criteria for persistent, high-impact pain criteria.\n* Presence of allodynia confirmed by one of the screening dynamic brush tests\n* women of childbearing potential who agree to abide by contraceptive requirements\n\nExclusion Criteria:\n\n* Actively engaged in or planning to enter a program of non-pharmacological invasive intervention for pain at the time of enrollment\n* Peripheral neuropathy is not a primary source of neuropathic pain\n* Hypersensitivity to THC, CBD, or THC\u002FCBD\n* Self-report of cannabis use during screening phase confirmed by positive urine toxicology for THC-COOH as measured and resulted at visit 5 before randomization\n* Unwilling to refrain from using cannabis or cannabis-based products through the entire duration of the study\n* Diagnosis of DSM-5 Cannabis Use Disorder in the past 6 months\n* Current DSM-5 diagnosis of cannabis use disorder, substance use disorder or serious psychiatric disorders\n* Actual change or intent to change is greater than a 20% change (increase or decrease) in any other medication for pain or non-pharmacological treatment from 4 weeks before the screening appointment until completion of study (i.e., visit 13)\n* Opioid doses \\> 400 mg MME (morphine milligram equivalent)\n* Women who are pregnant or breastfeeding, or who intend to become pregnant in the 12 weeks from enrollment\n* Any current unstable or concerning medical condition that would place the patient at increased risk, including hepatic, respiratory, immunological, cardiovascular, endocrine, or renal disease, or in the opinion of the investigator, prevents adherence with the protocol\n* Need for immediate psychiatric hospitalization\n* Enrolled in a medical marijuana program\n* Federal employee","21 Years",{"count":51,"type":21},320,[53],"PHASE2","Chronic neuropathic pain (CNP) is disabling. Research on frontline treatments for CNP, shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differing from that of civilians, a well-structured clinical trial of cannabinoids for Veterans with CNP is vital.",[56,28],"Neuropathic Pain","2026-02-23",{"date":59,"type":33},"2026-02-27",{"date":61,"type":33},"2023-06-21",{"date":63,"type":21},"2029-05-31",{"name":65,"class":66},"VA Office of Research and Development","FED",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100538425","clinical-trial-of-the-safety-and-efficacy-of-peripheral-nerve-stimulation-in-the-treatment-of-peripheral-neuropathic-pain-100538425","NCT06290661","Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.","Prospective, Multicentre, Randomised Withdrawal Design of a Clinical Trial Evaluating the Safety and Efficacy of a Percutaneous Peripheral Nerve Stimulation System for Patients With Peripheral Neuropathic Pain.","Inclusion criteria:\n\n* 18 years old and above, male or female\n* Diagnosed by trained clinical doctors as postherpetic neuralgia, which is an indication for peripheral nerve stimulation therapy;\n* Assess the damage or disease of the peripheral sensory system through the four questions of Douleur Neuropathy before surgery;\n* The subject has received conventional treatment but the efficacy is poor, or cannot tolerate the side effects of conventional treatment;\n* Visual analogue scale for pain within 24 hours before surgery ≥ 5;\n* The subjects are able to understand the purpose of this study, have sufficient compliance with the research treatment, and are willing to sign an informed consent form;\n\nExclusion criteria:\n\n* Subjects who need to receive both radio frequency modulation and intrathecal drug infusion treatment simultaneously;\n* Subjects who are known to have cardiac implants (pacemakers or defibrillators) or other implantable neural stimulators (spinal cord stimulators or deep brain stimulators, etc.);\n* Subjects with severe psychological and\u002For mental disorders and\u002For non therapeutic drug dependence;\n* Subjects expected to undergo MRI examination within 30 days after PNS implantation;\n* Expected to be discharged within 48 hours or less;\n* Target nerve damage or muscle defects in known pain areas;\n* Subjects who are known to be allergic to skin contact materials (tape or adhesive);\n* Allergy to anesthetics such as lidocaine;\n* Concomitant severe heart disease, liver disease, kidney disease, respiratory system disease, and coagulation dysfunction;\n* Pregnant women, lactating women, or women planning to have children within the next three months;\n* Subjects who have participated in any other clinical trial, or who may participate in any other trial after enrollment;\n* Other situations that the researcher deems unsuitable for participation in this clinical trial",{"count":75,"type":21},60,[24],"The goal of this clinical trial is to evaluate safety and efficacy of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain. The main questions it aims to answer are:\n\n1. The efficacy of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain\n2. The safety of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain Participants are going to undergo procedure that implant peripheral nerve stimulation electrode produced by Jiangsu CED Medtech Co., Ltd. Then the subjects, whose VAS scores decrease more 30% than baseline level, are classified into two groups randomly. One of the group receiving active stimulation called trial group and another receiving placebo stimulation called control group. All subjects are required to make their own subjects' pain diary to record VSA score before and after implantation until at the end of follow-up. Also, participants are asked to report use of analgesic medications, number of awakenings and adverse events.\n\nResearchers will compare pain scores between the two groups to see if peripheral nerve stimulation is effective to patients with peripheral neuropathic pain.",[79,28,80],"Postherpetic Neuralgia","Trigeminal Neuralgia",[82,83],"Peripheral Nerve Stimulation","peripheral neuropathic pain","2025-07-22",{"date":86,"type":33},"2025-07-28",{"date":88,"type":33},"2023-02-09",{"date":90,"type":21},"2026-12-30",{"name":92,"class":40},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":41},"100590194","protocol-assessment-of-motor-cortex-rtms-for-treating-neuropathic-pain-100590194","NCT06964243","Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain","Classical, Spaced, or Accelerated Transcranial Magnetic Stimulation of Motor Cortex for Treating Neuropathic Pain: a 3-arm Parallel Non-inferiority Study","CSA3-RTMS","Inclusion Criteria:\n\n* (1) existence of a definite peripheral neuropathy on both clinical and neurophysiological grounds, present for at least 6 months;\n* (2) neuropathic pain clearly related to the neuropathy, as defined by a score ≥ 4\u002F10 on the questionnaire \"Douleur Neuropathique en 4 Questions\" (DN4) ;\n* (3) a score ≥ 4\u002F10 on a 0-10 numerical rating scale (NRS) concerning the average intensity of daily ongoing pain;\n* (4) age between 18 and 80 years;\n* (5) affiliation with the social security system;\n* (6) ability to provide signed informed consent.\n\nExclusion Criteria:\n\n* (1) concomitant neurological (neurodegenerative disorders, migraine, epilepsy, stroke, tumor) or psychiatric illness;\n* (2) contraindications related to TMS (intracranial ferromagnetic material);\n* (3) drug-resistant or active epilepsy.","80 Years",{"count":103,"type":21},36,[24],"Neuropathic pain is frequent and drugs relieves only 50% of the patients. Repetitive transcranial magnetic stimulation (rTMS) at high frequency (HF, usually 10Hz) applied on the primary motor cortex (M1) is an effective treatment of neuropathic pain. For the treatment of chronic pain, the 'classical' HF-rTMS protocol (CHF-rTMS) include one daily session for one or two weeks as an induction phase of treatment followed by a weekly session to produce analgesic effects. However, another type of protocol is based on a more spaced repetition of HF-rTMS sessions (SHF-rTMS), including intervals of several days or weeks between two sessions, but also resulting in a significant pain relief. However, CHF-rTMS and SHF-rTMS have never been compared regarding their analgesic efficacy.\n\nAlongside with pain, depression is the other clinical condition for which HF-rTMS is proposed as an effective therapeutic strategy. Another type of rTMS paradigm, called \"accelerated intermittent theta burst stimulation\" (ACC-iTBS) protocol has been recently proposed for the treatment of depression, combining a high number of pulses delivered per session and a high number of short-duration sessions grouped into a few days of stimulation. However, this type of protocol has never been applied for the treatment of chronic pain patients.\n\nThus, for the first time we propose to compare in a pilot study the efficacy of three different rTMS protocols for the treatment of chronic neuropathic: CHF-rTMS, SHF-rTMS, and ACC-iTBS. In this study, two protocols two rTMS protocols (CHF-rTMS and ACC-iTBS) will share the same high total number of TMS pulses (i.e. 30 000 pulses) versus an rTMS protocol (SHF-rTMS) based on a lower total number of TMS pulses (i.e. 6 400 pulses), while one protocol (CHF-rTMS) will include a higher number of days of stimulation (i.e. 10 days) compared to the two other protocols (ACC-iTBS and SHF-rTMS) (i.e. 4 days). In all cases, the motor cortical target and the intensity of stimulation will the same.\n\nThus, this study will be able to appraise the respective influence of the number of pulses delivered (the higher the number, the greater the effect) and the number of sessions (the higher the number, the more restrictive the implementation of treatment). That is to say that the new ACC-iTBS protocol could be an optimal compromise of a more efficacious and more easy-to-perform rTMS protocol for the treatment of patients with chronic pain.",[107,28],"Chronic Pain Syndrome",[109,110,111,112,113,114,115,116,117,118],"rTMS","TMS-EEG","EEG","neuropathic pain","chronic pain","peripheral neuropathy","treatment","TBS","thetaburst stimulation","transcranial magnetic stimulation","2025-04-30",{"date":121,"type":33},"2025-05-09",{"date":123,"type":33},"2025-04-01",{"date":125,"type":21},"2027-02-01",{"name":127,"class":40},"Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100502079","response-profiles-to-high-concentration-capsaicin-desensitization-in-patients-with-peripheral-neuropathic-pain-with-or-without-allodynia-a-regional-multicenter-prospective-cohort-100502079","NCT05817591","Response Profiles to High-concentration Capsaicin Desensitization in Patients with Peripheral Neuropathic Pain with or Without Allodynia: a Regional Multicenter Prospective Cohort","CAPSICAURA","Inclusion Criteria:\n\n* Patient over 18 years of age on the day of inclusion\n* Patient who has been informed and has not expressed opposition to participating in the study,\n* Patient with peripheral neuropathic pain (whatever the etiology), defined by :\n\n  * \"Neuropathic Pain 4\" score (\"DN4\" score) ≥ 4\u002F10\n  * AND pain according to the numerical scale (EN) \\> 4\u002F10,\n  * AND stable analgesic treatment for at least 1 month,\n  * AND with or without mechanical allodynia according to the Quantitative Sensory Testing (QST) : Brush test (dynamic), Von Frey test (static)\n  * AND with or without thermal allodynia to hot or cold as determined by a ROLLTEMP-II® (Rolltemp is a device designed for quick screening of temperature sensibility over large body areas).\n* Patient responding to an indication of desensitization to high concentration capsaicin concentration and not presenting any contra-indication.\n* Patient naïve of high concentration of Capsaicin on the concerned zone\n* Patient understanding French\n\nNon-inclusion Criteria:\n\n* Patient with pain related to complex regional pain syndrome (criteria not meeting the indication for capsaicin)\n* Patient with active cancer (underlying disease and treatments may modify pain perception),\n* Patient receiving or having received in the last 3 months Botulinum toxin A on the concerned area (this treatment of neuropathic pain may modulate the effect of capsaicin and disturb the demonstration of causality),\n* Patient with planned surgery within the next 12 months on the painful site (surgery may cause neuropathic damage and\u002For bias the pain assessment),\n* Patient included in an interventional research protocol,\n* Patient under guardianship or curators,\n* Patient under legal protection\n\nExclusion Criteria:\n\nNone",{"count":136,"type":21},400,"OBSERVATIONAL","Prospective multicenter cohort to determine patient profiles (associated factors, including allodynia) with a better response to pain desensitization by capsaicin delivered in the form of a high concentration patch (8%), in a population of patients with peripheral neuropathic pain and followed up in a pain consultation in the Auvergne Rhône Alpes region.",[28],"2025-02-11",{"date":142,"type":33},"2025-02-13",{"date":144,"type":33},"2023-12-14",{"date":146,"type":21},"2026-06-15",{"name":148,"class":40},"Centre Hospitalier Annecy Genevois",10,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":157,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":178,"locationsCount":41},"100561896","phase-2-vitamin-d-supplementation-in-breast-cancer-patients-100561896","NCT06596122","Vitamin D Supplementation in Breast Cancer Patients","The Effect of Vitamin D Supplementation in Breast Cancer Patients Receiving Taxane-based Chemotherapy","Inclusion Criteria:\n\n1. Female aged 18 to 65 years old.\n2. Histologically confirmed breast cancer.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 \\[21\\] \\[22\\].\n4. All patients should fulfill the criteria of the initiation of taxane-based chemotherapy such as absolute neutrophil count (ANC) \\> 1,500\u002FmcL, platelets \\> 100,000\u002FmcL, hemoglobin ≥ 9 g\u002FmL, Aspartate Aminotransferase (AST) (Serum Glutamic-Oxaloacetic Transaminase) (SGOT) to Alanine Aminotransferase (ALT), (Serum Glutamic-Pyruvic Transaminase) (SGPY) ratio (AST (SGOT)\u002FALT (SGPT)) \\< 2.5 x institutional upper limit of normal (ULN), total bilirubin less than or equal to 1.5 x institutional ULN, serum creatinine \\< 1.5 x institutional ULN.\n5. Stage I-III breast cancer scheduled to undergo adjuvant or neoadjuvant paclitaxel-based chemotherapy for breast cancer using doxorubicin 60 mg\u002Fm² and cyclophosphamide 600 mg\u002Fm² followed by paclitaxel 80 mg\u002Fm² weekly for 12 weeks protocol code BRAJACTW \\[23\\].\n6. Vitamin D insufficiency defined as serum level \\< 30 ng\u002Fml.\n7. Ability to give informed consent as per the legal requirement.\n\nExclusion Criteria:\n\n1. Prior neurotoxic chemotherapy including paclitaxel.\n2. Metastatic carcinoma.\n3. History of any other malignancy except malignancy that was treated with curative intent and for which there has been no known active disease for more than 3 years prior to randomization, curatively treated non-melanoma skin malignancy, cervical cancer in situ, in situ ductal carcinoma, or breast in situ lobular carcinoma.\n4. Grade II neuropathy or higher based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. neurosensory or neuromotor neuropathy, regardless of causality.\n5. Patients who are scheduled to receive any neurotoxic chemotherapeutic agents such as platinum compounds (carboplatin, cisplatin), vinorelbine, eribulin, and ixabepilone.\n6. Diabetes mellitus\n7. Psychiatric disorders that limit ability to comply with study protocol i.e., history of regular exacerbation of major psychosis (schizophrenia, bipolar disorder) in last 2 years.\n8. Known Fibromyalgia\n9. Gastric bypass surgery.\n10. Patients with chronic granuloma forming disorders (sarcoidosis or tuberculosis TB).\n11. Known hyperparathyroidism.\n12. Known thyroid dysfunction.\n13. Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.\n14. Pregnancy and lactation.\n15. Hypercalcemia (corrected blood calcium \\> 10.5 mg\u002Fdl or \\> 2.6 mmol\u002FL)\\[24\\]\n16. Hyperphosphatemia, serum phosphate concentration \\> 4.5 mg\u002FdL \\[25\\]\n17. History of symptomatic genitourinary stones within the past year.\n18. Allergy to any cholecalciferol dosage form component.\n19. Alcohol consumption.\n20. Regular use of vitamin D \\> 2000 IU daily over the past year.\n21. Inability to swallow pills.\n22. Medications that may interfere with vitamin D metabolism, including enzyme inducing anticonvulsants, lithium, phenytoin, verapamil, orlistat, tuberculosis medications as isoniazid, and\u002For rifampin and estrogen-containing medications.\n23. Patients receiving any of the following medications used to prevent CIPN: vitamin E, glutamine, nortriptyline, amitriptyline, tricyclic antidepressants, pregabalin, and duloxetine and other nutritional supplements as vitamin B during taxane administration.","FEMALE","65 Years",{"count":160,"type":21},132,[53],"It is a randomized clinical trial aimed at exploring the neuroprotective effect of vitamin D3 (Cholecalciferol) supplementation in conjunction with paclitaxel-based chemotherapy among breast cancer patients with vitamin D insufficiency or deficiency.",[28],[165,166,167,168,169,170],"Cholecalciferol","Breast cancer","Neuropathic pain","Taxane","Paclitaxel","Vitamin D3","NOT_YET_RECRUITING","2024-09-11",{"date":174,"type":33},"2024-09-19",{"date":176,"type":21},"2024-10-15",{"date":90,"type":21},{"name":179,"class":40},"Abdelrahman Mahmoud"]